CHGX

ChitogenX Inc. (CHGX)

Market Closed
10 Jun, 20:00
CNSX CNSX
CA$
0. 01
0
0%
CA$
- Market Cap
- P/E Ratio
0% Div Yield
120,000 Volume
- Eps
CA$ 0.01
Previous Close
Day Range
0.01 0.01
Year Range
0.01 0.04
Want to track CHGX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 1 days

Summary

CHGX closed Tuesday higher at CA$0.01, an increase of 0% from Monday's close, completing a monthly increase of 0% or CA$0. Over the past 12 months, CHGX stock lost -66.67%.
CHGX is not paying dividends to its shareholders.
The last earnings report, released on Dec 08, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Dec 15, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on CNSX (CAD).

CHGX Chart

ChitogenX Inc. (CHGX) FAQ

What is the stock price today?

The current price is CA$0.01.

On which exchange is it traded?

ChitogenX Inc. is listed on CNSX.

What is its stock symbol?

The ticker symbol is CHGX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Dec 15, 2025.

Has ChitogenX Inc. ever had a stock split?

No, there has never been a stock split.

ChitogenX Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Pierre Laurin B.Sc.Pharm., M.Sc. CEO
CNSX Exchange
- ISIN
CA Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

ChitogenX Inc., initially known as Ortho Regenerative Technologies Inc., is pivotal in the field of orthopaedic and sports medicine biologics, primarily within Canada. The company, which was founded in 2015 and later rebranded to ChitogenX Inc. in September 2022, is headquartered in Kirkland, Canada. It specializes in the research and development of innovative therapeutic soft tissue repair technologies. Their work is aimed at enhancing the success rates of orthopaedic and sports medicine surgeries through the development of novel biopolymers, positioning ChitogenX Inc. as a leader in orthopaedic biologics R&D.

Products and Services

Ortho-R: ChitogenX's flagship product, Ortho-R, is a biopolymer specifically designed for rotator cuff repair. This innovation targets one of the most common injuries within the field of sports medicine and orthopaedics, providing a novel approach to enhance the healing process. The technology behind Ortho-R aims at improving the integration and repair of the rotator cuff, which could significantly improve outcomes for patients undergoing such surgeries.

Ortho-M: Another groundbreaking product from ChitogenX Inc. is Ortho-M, a biopolymer developed for meniscus repair. Like Ortho-R, Ortho-M employs cutting-edge biopolymer technology to advance the healing of meniscal tears, which are prevalent in both sporting and non-sporting populations. This product stands out for its focus on enhancing the body's natural healing capacity, potentially leading to better surgical outcomes and faster recovery times for patients facing meniscus-related issues.

Contact Information

Address: 16667 Hymus Boulevard
Phone: 514-782-0951